AlzGene - Gene overview of all published AD-association studies for CYP46A1
Back Search Methods Disclaimer Credits
 Gene: CYP46A1  (CP46; CYP46)  Entrez Gene
 Protein: cytochrome P450, family 46, subfamily A, polypeptide 1   ProteinLink
 Chromosome: 14   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 29 January 2010
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      AD Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result Comment
 Caucasian
Borroni, 2004
 Italy CL  1  (detail)  157
(62%)		C-72.2 + 7.9
(-)		134
(-)		-Positive
Chalmers, 2004
 UK CL  1  (detail)  86
(53%)		N-79.5 + 7.2
(60-93)		58
(41%)		78.8 + 8.2
(62-95)		Negative
Combarros, 2004
 Spain CL  1  (detail)  321
(68%)		C71.9 + 8.8
(48-95)		75.6 + 9
(50-98)		315
(70%)		80.3 + 7.7
(63-100)		Positive
Del Pozo, 2005
 Spain CL  1  (detail)  100
(76%)		C71.7 + 8.3
(-)		75.1 + 7.8
(-)		119
(62%)		77.6 + 9.7
(-)		Positive
Desai, 2002
 USA CL  1  (detail)  434
(70%)		M71.2 + 6.1
(-)		77.5 + 6.6
(-)		401
(62%)		74.7 + 5
(-)		Negative
Giedraitis, 2009
 Sweden (ULSAM) CL  2  (detail)  86
(0%)		C80.2
(72-85)		-404
(0%)		81.8
(80-84)		Negative
Golanska, 2005
 Poland    2  (detail)  215
(67%)		C71.4 + 5.2
(-)		76.7 + 5.1
(59-89)		173
(76%)		71.9 + 6.4
(60-88)		Positive
Golanska, 2009
 Overlaps with
Golanska, 2005		 CL  2  (detail)  213
(67%)		C71.4 + 5.2
(56-84)		76.7 + 5.2
(62-89)		171
(75%)		71.9 + 6.4
(60-88)		n.a.
Helisalmi, 2006
 Finland CL  1  (detail)  422
(69%)		C72 + 7
(-)		-469
(61%)		70 + 5
(-)		Positive
Johansson, 2004
 Sweden (Set A) CL  2  (detail)  452
(61%)		C73.3 + 7.6
(-)		76.3 + 7
(-)		403
(67%)		79.9 + 4.1
(-)		Negative
Johansson, 2004
 Sweden (Set B) CL  2  (detail)  93
(62%)		N69.8 + 10.2
(-)		80.2 + 8.2
(-)		102
(44%)		76.7 + 9.6
(-)		Negative
Johansson, 2004
 Scotland CL  2  (detail)  121
(58%)		C52.4 + 6.8
(-)		57.8 + 6.3
(-)		152
(38%)		58.2 + 9.8
(-)		Negative
Juhasz, 2005
 Hungary CL  1  (detail)  125
(63%)		C-74.4 + 6.4
(-)		102
(56%)		73.5 + 5.3
(-)		Negative
Kabbara, 2004
 France CL  1  (detail)  601
(61%)		C69.5 + 7.4
(-)		72.4 + 7.2
(-)		631
(64%)		72.5 + 7.9
(-)		Negative
Koelsch, 2002
 Overlaps with
Koelsch, 2009		 CL  2  (detail)  114
(64%)		C-71.5 + 8.4
(-)		144
(53%)		68.8 + 13.4
(-)		Positive
Koelsch, 2009
 Germany CL  16  (detail)  455
(68%)		C-73.1 + 8.6
(53-101)		327
(54%)		73.9 + 7.5
(65-100)		Positive
Papassotiropoulos, 2003
 I (Greece, Italy) CL  1  (detail)  107
(64%)		C-72.7 + 5.6
(-)		76
(66%)		72.9 + 4.8
(-)		Positive
Papassotiropoulos, 2003
 II (Switzerland) CL  1  (detail)  94
(53%)		C-75.2 + 7.3
(-)		172
(42%)		74.4 + 6.8
(-)		Positive
Papassotiropoulos, 2005
 Overlaps with
Papassotiropoulos, 2003 (I)		 CL  1  (detail)  ------n.a.
Papassotiropoulos, 2005
 Overlaps with
Papassotiropoulos, 2003 (II)		 CL  1  (detail)  ------n.a.
Shibata, 2005
 USA, Canada CL  2  (detail)  218
(53%)		C75 + 8.4
(-)		-195
(52%)		73.1 + 9.3
(-)		Negative
Tedde, 2005
 Italy CL  1  (detail)  296
(66%)		M70.6 + 5.5
(-)		-177
(72%)		83.3 + 18.7
(-)		Negative
 African Descent
Desai, 2002
 USA CL  1  (detail)  54
(72%)		M72.1 + 5.6
(-)		76.9 + 5.6
(-)		61
(75%)		70.9 + 6.1
(-)		Negative
 Asian
Li, 2006
 China CL  2  (detail)  130
(81%)		C-78.9 + 6
(65-93)		110
(71%)		72.1 + 5.8
(65-90)		Positive
Ma, 2006
 China CL  4  (detail)  182
(82%)		C-78
(66-97)		179
(75%)		73
(65-89)		Positive
Wang, 2004
 China CL  1  (detail)  99
(51%)		C-78.9 + 6.5
(64-97)		113
(31%)		68 + 2.8
(65-77)		Positive
Wang, 2007
 China CL  1  (detail)  168
(56%)		C69.3 + 7.3
(-)		73.5 + 8.4
(-)		215
(63%)		72.3 + 7.6
(-)		Negative
 Other/Mixed
Ingelsson, 2004
 USA CL  1  (detail)  178
(65%)		M-76.8
(-)		105
(56%)		67.6
(-)		Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis ->  "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
AlzGene Top Results
Top Results Details
1. APOE_e2/3/4
2. BIN1
3. CLU
4. ABCA7
5. CR1
6. PICALM
7. MS4A6A
8. CD33
9. MS4A4E
10. CD2AP
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Cure Alzheimer's Fund
Proud supporter of the AlzGene database.
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.

NCRAD
The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.